烏龍製藥 URGN 深 滬
等待開盤 11-04 09:30:00 美东时间
34.40
+0.040
+0.12%
華盛通- 最 高34.97
- 今 開34.50
- 成交量 123.76万股
- 最 低 34.00
- 昨 收 34.36
- 總市值 16.81亿
- 52周最高 50.81
- 市盈率 靜 --
- 換手率 2.53%
- 52周最低 16.50
- 委 比 -16.55%
- 總股本 4888.06万
- 歷史最高 69.568
- 量 比 0.85
- 振 幅 2.82%
- 歷史最低 3.42
- 每 手 1
- 風險率 9.44%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多UroGen Pharma收涨5.01%，成交额6955.1万美元
11月3日，UroGen Pharma（URGN）收涨5.01%，报34.36美元，成交额6955.1万美元，市值16.8亿美元。 行情数据 • 开盘价：32...
11-03 06:30
UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer
UroGen Pharma announced the publication of five-year follow-up data from the Olympus study in *Therapeutic Advances in Urology*, highlighting JELMYTO's long-term efficacy in treating low-grade upper tract urothelial cancer (LG-UTUC). Among 41 patients achieving complete response, the median duration of response was 47.8 months, with no progression to high-grade disease observed. The findings support JELMYTO as a durable, kidney-sparing treatment ...
10-28 12:00
UroGen Pharma收跌1.88%，成交额2519.14万美元
10月24日，UroGen Pharma（URGN）收跌1.88%，报34.49美元，成交额2519.14万美元，市值16.86亿美元。 行情数据 • 开盘价...
10-24 05:33
美股大行评级 | 潜在涨幅523.44%！HC Wainwright & Co.上调Annexon目标价至25美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Annexon"买入"评级，目标价从14美元升至25美元；HC Wainwright & Co.：维持Alto Neuroscience"买入"评级，目标价从55美元升至60美元
10-20 12:36
HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $75 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $75 price target.
10-19 22:31
UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC
UroGen Pharma announced the FDA acceptance of its NDA for UGN-103, an investigational intravesical mitomycin solution for treating adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The FDA has set a PDUFA target action date of June 14, 2027. UGN-103 combines UroGen's proprietary RTGel technology with a novel mitomycin formulation, offering a streamlined manufacturing process and simplified reconst...
10-19 12:00
UroGen Pharma收跌5.6%，成交额3630.87万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 05:33
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. has granted inducement restricted stock units (RSUs) to 19 new employees to support the commercialization of its approved products, JELMYTO® and ZUSDURI™, and pipeline development. The RSUs, totaling up to 117,100 shares, vest equally over three years. The grants align with Nasdaq Listing Rule 5635(c)(4) and UroGen’s 2019 Inducement Plan. UroGen, headquartered in Princeton, NJ, specializes in innovative treatments for urothelia...
09-04 12:00
UroGen Pharma to Present at Upcoming Investor Conferences
UroGen Pharma Ltd. will participate in three investor conferences in September 2026. The events include the Wells Fargo 21st Annual Healthcare Conference on September 9th in Boston, the Cantor Global Healthcare Conference 2026 on September 10th in New York, and the H.C. Wainwright 28th Annual Global Investment Conference on September 15th in New York. Each session will be a Fireside Chat and webcast links are provided. The webcasts will also be a...
09-02 12:00
UroGen Pharma Announces Strategic Option And Research License Agreement And Related Equity Investment Agreement With IntraGel Therapeutics
Collaboration grants UroGen a research license and exclusive options to license and develop up to three oncology products utilizing IntraGel's proprietary SRGel platform Agreement also includes an exclusive option to acquire worldwide rights to TumoCure, an investigational therapy for advanced head ...
08-20 19:02
